|
Library license
March 2017
SHARING OPTIONS:
CAMBRIDGE, U.K.—Isogenica Ltd. and Maverick
Therapeutics, an MPM Capital portfolio company, have joined forces in a license agreement centered around Isogenica’s family of antibody libraries. Per
the deal, Maverick has received a license to Isogenica’s llamdA VHH single-domain antibody libraries for the discovery, development and
commercialization of therapeutic products derived from the libraries. In return, Isogenica stands to receive an upfront payment as well as annual license
payments and, should antibodies be moved into development, additional commercial upfront and milestone payments. No specific financial details were
disclosed. Isogenica’s libraries can be screened in a variety of formats, including phage and CIS-Display, a proprietary in-vitro display
technology that maintains the libraries’ diversity through the discovery process.
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|